Scarica l'app Stockscreener
8.70
1.05%
0.09
Dopo l'orario di chiusura:
8.77
0.07
+0.80%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IBRX Giù?
Forum
Previsione
Immunitybio Inc Borsa (IBRX) Ultime notizie
ImmunityBio Stock Surges on Bold Global Expansion - TipRanks
ImmunityBio Inks Partnerships To Launch Cancer Drug In Saudi Arabia Amid Expansion Efforts - Asianet Newsable
ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients - BioSpace
ImmunityBio partners with distributors to launch Anktiva in Saudi Arabia - Investing.com
ImmunityBio Taps 85-Person Sales Team to Launch Its Bladder Cancer Drug In European Countries - Bitget
ImmunityBio, Inc. has partnered with Biopharma and Cigalah Healthcare to officially launch its innovative therapy Anktiva® in the Saudi Arabian market. - Bitget
ImmunityBio to launch ANKTIVA® in Saudi Arabia for bladder and lung cancer treatment - BioSpectrum Asia
ImmunityBio Wins EU Nod for Bladder Cancer Combo Therapy, Stock Up - The Globe and Mail
IBRX Stock Rally Not Over Yet? Chairman Says Trump Diplomacy Led To ‘Amazing Results’ For Cancer Drug - Stocktwits
Conditional Approval for ANKTIVA in BCG-Unresponsive Non-Muscle Invasive Bladder CancerImmunityBio - Oncodaily
European Approval Ignites Surge for ImmunityBio Shares - AD HOC NEWS
ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch - BioSpace
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc.IBRX - PR Newswire
ImmunityBio Wins EU Anktiva Nod As Investors Weigh Execution Risks - simplywall.st
ImmunityBio Stock Soars 42% After New Anktiva Approvals. Here’s What’s Driving the Rally - TIKR.com
ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsi - PharmiWeb.com
ImmunityBio Stock Maintains Golden Cross Signal - Intellectia AI
ImmunityBio (NASDAQ:IBRX) Shares Gap DownShould You Sell? - MarketBeat
ImmunityBio Holds Golden Cross As Stock Trades 170% Above 200-Day Average - Benzinga
Regulatory Challenges Impact ImmunityBio Shares - timothysykes.com
ImmunityBio, Accord Healthcare Collaborate to Expand Anktiva Access in Europe - marketscreener.com
ImmunityBio Partners with Accord Healthcare to Expand Anktiva Access - Intellectia AI
ImmunityBio (IBRX): The Rise of Immunotherapy 2.0 and the Global Expansion of ANKTIVA - FinancialContent
ImmunityBio Announces Partnership To Expand Access To Anktiva Across 30 Countries - Stocktwits
ImmunityBio partners with Accord Healthcare to expand ANKTIVA across Europe - Investing.com
ImmunityBio, Inc. announces the expansion of access to its innovative drug Anktiva® in the EU through a new distribution partnership, while officially establishing an Irish subsidiary to provide strategic support for the comprehensive promotion of its products in - Bitget
ImmunityBio inks deal for Anktiva access in Europe (IBRX:NASDAQ) - Seeking Alpha
ImmunityBio (IBRX) Stock Jumps as EU Clears ANKTIVA for Bladder Cancer - Blockonomi
ImmunityBio (IBRX) Is Up 29.0% After EU Clears First ANKTIVA+BCG Immunotherapy For NMIBC CIS - Yahoo Finance
ImmunityBio (IBRX) Soars to New High on Anktiva Future Expansion - Insider Monkey
ImmunityBio’s EU Anktiva Nod Sparks Questions On Valuation And Momentum - Yahoo Finance
ImmunityBio (IBRX) Moves 41.9% Higher: Will This Strength Last? - Nasdaq
ImmunityBio (IBRX) Stock Jumps as ANKTIVA Becomes First Approved Bladder Cancer Immunotherapy in Europe - CoinCentral
ImmunityBio Soars Over 40% as European Commission Approves Bladder Cancer Drug Anktiva - NAI500
Institution Moves: Does ImmunityBio Inc have a sustainable dividendTake Profit & Reliable Entry Point Trade Alerts - baoquankhu1.vn
ImmunityBio's Short Interest Turns Bullish Ahead of EU Decision - Intellectia AI
European Commission authorizes ImmunityBio’s ANKTIVA for bladder cancer By Investing.com - Investing.com South Africa
ImmunityBio (IBRX) Clinical Trial for Lymphona Drug Follows $505M Convertible Note Change - Finviz
ImmunityBio (NASDAQ:IBRX) Trading 41.9% HigherWhat's Next? - MarketBeat
ImmunityBio Stock Soars After EU Grants Conditional Approval for Anktiva - Intellectia AI
Stock Market Today, Feb. 18: ImmunityBio Soars After EU Approves ANKTIVA for Bladder Cancer - AOL.com
ImmunityBio (NASDAQ:IBRX) Hits New 52-Week HighShould You Buy? - MarketBeat
Stock Market Today, Feb. 18: ImmunityBio Soars After EU Approves ANKTIVA for Bladder Cancer - The Motley Fool
IBRX Stock Quote Price and Forecast - CNN
Anktiva Vs Keytruda: ImmunityBio Exec Chair Slams FDA For Double Standards In Approvals - Stocktwits
Immunitybio stock hits 52-week high at $8.28 - Investing.com
Why ImmunityBio Stock Is Soaring Today - AOL.com
ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries - BioSpace
ImmunityBio Shares Rise After EU Conditional Authorization for Anktiva With BCG - marketscreener.com
What's Behind The Jump In ImmunityBio Stock? - Benzinga
Why Is ImmunityBio (IBRX) Rallying Today? EU Approves Anktiva - Tokenist
Why ImmunityBio Stock Is Quietly Breaking Out - TipRanks
ImmunityBio (IBRX) jumps ahead of oncology event - MSN
ImmunityBio Stock Gains 19% Over Conditional Marketing Authorization From EC For ANKTIVA - Nasdaq
ImmunityBio stock soars after EU authorization for bladder cancer therapy - Investing.com Nigeria
0.66%
0.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):